

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Vamikibart for treating uveitic macular oedema ID6671

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<u>Company</u> • Roche (vamikibart) <u>Patient/carer groups</u> • Birdshot Uveitis Society • Eyecare Trust • Fight for Sight • Macular Society • National Federation of the Blind of the UK • Retina UK • Royal National Institute of Blind People (RNIB) • SeeAbility • South Asian Health Foundation • Specialised Healthcare Alliance • Thomas Pocklington Trust <u>Healthcare professional groups</u> • Association of Optometrists • British & Irish Paediatric Ophthalmology and Strabismus Association • British and Irish Orthoptic Society • British Geriatrics Society • British Ophthalmic Anaesthesia Society • College of Optometrists • Optical Confederation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association	<u>General</u> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Uveitis Information Group (Scotland) • Wales Council for the Blind • Welsh Government <u>Possible comparator companies</u> • Abbvie (adalimumab, dexamethasone intravitreal implant) • Alimera Sciences (fluocinolone acetonide intravitreal implant) • Amgen (adalimumab) • Aspen (chlorambucil) • Astellas Pharma (tacrolimus) • Aurobindo Pharma – Milpharm (mycophenolate) • Baxter Healthcare (cyclophosphamide) • Biogen Biosimilars (adalimumab, infliximab) • Celltrion Healthcare UK (adalimumab, infliximab, rituximab)

Provisional stakeholder list for the evaluation of vamikibart for treating uveitic macular oedema ID6671

Issue date: M 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 1 of 4

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<u>Others</u> • Department of Health and Social Care • NHS England	• Chiesi Limited (tacrolimus) • Cipla EU (methotrexate) • Dexcel Pharma (ciclosporin) • Dr Reddy's Laboratories (UK) (rituximab) • Esteve Pharmaceuticals (methotrexate) • Fresenius Kabi (adalimumab) • Hospira UK (methotrexate) • Janssen-Cilag (infliximab) • Medac Pharma (methotrexate) • Morningside Healthcare (ciclosporin, methotrexate) • Nova Laboratories (azathioprine) • Novartis Pharmaceuticals UK (ciclosporin) • Orion Pharma (UK) (methotrexate) • Pfizer (infliximab, rituximab) • Ranbaxy (UK) (ciclosporin) • Roche Products (mycophenolate, rituximab) • Rosemont Pharmaceuticals (methotrexate, mycophenolate) • Sandoz (adalimumab, cyclophosphamide, infliximab, methotrexate, mycophenolate, rituximab, tacrolimus) • Santen UK (ciclosporin) • Seacross Pharmaceuticals (cyclophosphamide) • Strides Pharma UK (azathioprine) • Teva Pharma (mycophenolate) • Thea Pharmaceuticals (ciclosporin) • Tillomed Laboratories (azathioprine, mycophenolate) • Viartis (ciclosporin) <u>Relevant research groups</u> • Cochrane Eyes and Vision Group • Eye Hope • Genomics England • Institute of Ophthalmology, University College London • International Uveitis Study Group • MRC Clinical Trials Unit

Provisional stakeholder list for the evaluation of vamikibart for treating uveitic macular oedema

ID6671

Issue date: M 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 2 of 4

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	• National Eye Research Centre • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.